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ABSTRACT*
Background: Escherichia coli (E. coli) is a frequent
uropathogen in urinary tract infections (UTI).
Widespread resistance to sulfamethoxazoletrimethoprim (SMX-TMP) and increasing resistance
to fluoroquinolones amongst these isolates has
been recognized. There are limited data
demonstrating risk factors for resistance to both
SMX-TMP and fluoroquinolones.
Objectives: This study was conducted to assess for
the prevalence of community resistance amongst E.
coli isolates to SMX-TMP and levofloxacin in
ambulatory patients discharged from the emergency
department (ED).
Methods: Adults presenting for evaluation and
discharged from the ED with a diagnosis of an E.
coli UTI were retrospectively reviewed. Utilizing
demographic and clinical data the prevalence of E.
coli resistance and risk factors associated with
SMX-TMP- and fluoroquinolone-resistant infection
were determined.
Results: Among the 222 patients, the mean rates of
E. coli susceptibility to levofloxacin and SMX-TMP
were 82.4% and 72.5%, respectively. Significant
risk factors for resistance to SMX-TMP included
prior antibiotic use (p=0.04) and prior diagnosis of
UTI (p= 0.01). Significant risk factors for resistance
to levofloxacin included: male gender, age,
presence of hypertension, diabetes, chronic
respiratory disease, nursing home resident,
previous antibiotic use, previous diagnosis of UTI,
existence of renal or genitourinary abnormalities,
and prior surgical procedures (p <0.05 for all
comparisons). The number of hospital days prior to
initial ED evaluation (p<0.001) was determined to
be a predictive factor in hospital and ED
readmission.
Conclusions: These results suggest that
conventional approaches to monitoring for patterns
of susceptibility may be inadequate. It is imperative
that practitioners develop novel approaches to
identifying patients with risk factors for resistance.
Identification of risk factors from this evaluation
should prompt providers to scrutinize the use of
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these agents in the setting of patients presenting
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ANÁLISIS DE PREVALENCIA Y FACTORES
DE RIESGO DE INFECCIONES DEL
TRACTO URINARIO POR ESCHERICHIA
COLI EN EL SERVICIO DE URGENCIAS
RESUMEN

Antecedentes: Escherichia coli (E. coli) es un
uropatogeno frecuente en infecciones del tracto
urinario (UTI). Se ha reconocido la resistencia
generalizada al sulfametoxazol-Trimetoprim
(SMX-TMP) y la resistencia creciente a
fluoroquinolonas entre los aislados. Hay datos
limitados que muestren los factores de riesgo para
la resistencia tanto a SMX-TMP como a
fluoroquinolonas.
Objetivos: Este estudio fue realizado para evaluar
la prevalencia de resistencia en la comunidad en
aislamientos de E. coli a SMX-TMP y
levofloxacino en pacientes ambulatorios dados de
alta en un servicio de urgencias (ED).
Métodos: Se revisó retrospectivamente a los
adultos que se presentaron para evaluación y fueron
dados de alta del ED con un diagnóstico de una
UTI con E. coli. Utilizando datos demográficos y
clínicos se calculó la prevalencia de resistencias a
E. coli y los factores de riesgo asociados a
infecciones resistentes a SMX-TMP y
fluoroquinolonas.
Resultados: Entre los 222 pacientes, las tasas
medias de susceptibilidad a levofloxacino y SMXTMP fueron de 82,4% y 72,5%, respectivamente.
Los factores de riesgo significativos para la
resistencia a SMX-TMP incluían el uso previo del
antibiótico (p=0,04) y el diagnóstico previo de UTI
(p=0,01). Los factores de riesgo significativos para
resistencia a levofloxacino incluían sexo masculino,
edad, presencia de hipertensión, diabetes,
enfermedad respiratoria crónica, vivir en residencia
de ancianos, uso previo del antibiótico, diagnóstico
previo de UTI, existencia de anomalías renales o
genitourinarias , y cirugías previas (p<0,05 para
todas las asociaciones). El número de días
anteriores a la evaluación inicial en el ED
(p<0,001) se identificó como un factor predictivo
de readmisión hospitalaria y al ED.
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Conclusiones: Estos resultados sugieren que los
abordajes convencionales para monitorizar los
patrones de susceptibilidad pueden ser inadecuados.
Es necesario que los facultativos desarrollen nuevos
abordajes para identificar pacientes con factores de
riesgo de resistencias. La identificación de los
factores de riesgo para esta evaluación debería
impulsar a los profesionales a examinar el uso de
estos antibióticos en los pacientes que presentan
una UTI no complicada en el ED.
Palabras clave: Farmacorresistencia Bacteriana;
Factores de Riesgo; Infecciones Urinarias;
Escherichia coli Uropatógena; Combinación
Trimetoprim-Sulfametoxazol; Fluoroquinolonas;
Servicio de Urgencia en Hospital; Estados Unidos.

the selective use of SMX-TMP for the treatment of
1
uncomplicated cystitis. The recommendation for
the use of fluoroquinolones is for complicated
infections, such as pyelonephritis, or if the local
1
resistance to SMX-TMP is ≥ 20%.
Presently practitioners are faced with widespread
resistance to SMX-TMP outside of the hospital and
increasing resistance to fluoroquinolones both
3,8,12
It was
within and outside the hospital setting.
the aim of this study to assess for the prevalence of
community resistance amongst E. coli isolates to
SMX-TMP and levofloxacin in ambulatory patients
discharged from the emergency department (ED)
with urinary tract infections; while also analyzing if
any risk factors were associated with readmission to
the ED and the hospital.
METHODS

INTRODUCTION
Escherichia coli (E. coli) is the most notable
pathogen that results in a frequently diagnosed
community-acquired infection, the urinary tract
1
infection (UTI). The recommended first line agents
for
uncomplicated
UTI
include
sulfamethoxazole/trimethoprim
(SMX-TMP)
or
2-5
However,
decreasing
nitrofurantoin.
susceptibilities of common pathogens to these
pharmacologic agents for the treatment of UTIs has
complicated empiric drug therapy decisions.
From 1999-2002, in-vitro rates of resistance to
SMX-TMP were noted to be increasingly prevalent,
1
while treatment failure rates remained stable.
Although, since that time rates of treatment failure
have risen in proportion to escalating in-vitro
resistance which now approaches or exceeds 20%
2-5
across the nation. Nevertheless, despite diffuse
SMX-TMP resistance E. coli resistance rates to
fluoroquinolones in North America have remained
low (3-6%) and trepidation concerning increasing
rates of resistance was primarily isolated to areas
6-9
outside of North America.
This has changed in the last five years as clinical
data from North America has been presented
identifying changing susceptibility patterns in gram
negative
bacilli
to
both
SMX-TMP
and
10,11
Despite these publications,
fluoroquinolones.
the most recent guidelines continue to recommend

Design
Following the obtainment of institutional review
board approval, patients aged ≥18 years who were
evaluated and discharged from the ED with a
discharge diagnosis of a UTI and a positive urine
culture for Escherichia coli from 2009-2011 were
retrospectively reviewed. Patients were identified
using an existing culture database that houses all
positive cultures from ambulatory patients seen
through, and discharged from, the ED. Only patients
with a positive urine culture were selected from the
database for further evaluation. Patients were
excluded for pregnancy or if their initial evaluation
resulted in an admission to the hospital.
Measurements
The primary objective of this study was to assess
the prevalence of and risk factors for E. coli
resistance to SMX-TMP and levofloxacin. The
secondary objectives included: assessing risk
factors for readmission, comparing the institutional
antibiogram to ED specific resistance rates, and
evaluating this resistance profile in six month
increments over three years to discern any possible
evolving resistance patterns. As part of the
secondary objective, a susceptibility profile was
created from the isolates collected, which permitted
the detection of resistance patterns of E. coli to
SMX-TMP and levofloxacin in ambulatory patients
presenting to the ED.

Table 1. Risk Factors for E. coli Resistance to Levofloxacin
Levofloxacin resistance,
Category
n, % (n=39)
Sex, male
13 (33.3%)
Race
White
33 (84.6%)
African-American
4 (10.2%)
Other
2 (5.1%)
Diabetes mellitus
10 (25.6%)
Hypertension
17 (43.6%)
Chronic respiratory disease
9 (23.1%)
Benign prostatic hypertrophy (BPH)
4 (10.3%)
Nursing home resident
7 (17.9%)
Antibiotic use within 90 days
26 (66.7%)
Previous UTI within 90 days
22 (56.4%)
Renal or genito-urinary abnormality
27 (69.2%)
Immunosuppression
5 (12.8%)
Home use of antibiotics
3 (7.7%)
Surgical procedures within 30 days
8 (20.5%)

Levofloxacin susceptible,
n, % (n=183)
28 (15.3%)
137 (74.9%)
26 (14.2%)
20 (10.9%)
31 (16.9%)
25 (13.7%)
7 (3.8%)
1 (0.6%)
0 (0%)
11 (6.0%)
9 (4.9%)
16 (8.7%)
7 (3.8%)
2 (1.1%)
7 (3.8%)
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p-value
0.016
0.272

0.296
<0.001
<0.001
0.003
<0.001
<0.001
<0.001
<0.001
0.062
0.054
<0.001

97

Bailey AM, Weant KA, Baker SN. Prevalence and risk factor analysis of resistant Escherichia coli urinary tract
infections in the emergency department. Pharmacy Practice 2013 Apr-Jun;11(2):96-101.
Table 2. Logistic Regression Analysis of Risk Factors for Levofloxacin and SMX-TMP Resistance
Variable
OR
95% CI
Levofloxacin Resistance
Age
0.972
0.952-0.991
Height
0.875
0.759-1.009
Weight
1.103
0.963-1.263
Body Mass Index (BMI)
0.753
0.522-1.088
Hospital days prior
1.014
0.961-1.071
Number days after emergency department
1.003
0.996-1.010
SMX-TMP Resistance
Age
1.005
0.988-1.024
Height
0.984
0.859-1.128
Weight
1.026
0.898-1.174
Body Mass Index (BMI)
0.938
0.653-1.346
Hospital days prior
1.016
0.954-1.082
Number days after emergency department
0.997
0.991-1.003

Data collected included patient demographic
information, co-morbid disease state diagnoses,
surgical procedures within 30 days prior to visit,
previous diagnosis of UTI within 90 days, renal or
genitourinary
abnormalities,
utilization
of
immunosuppression or antimicrobial prophylaxis,
history of antibiotic use within 90 days, pertinent
laboratory data, pertinent culture data with reported
susceptibility patterns, antibiotic prescribed upon
discharge and duration of therapy, and number of
hospital days prior to the initial ED evaluation. The
number of hospital days was calculated based on
the total number of documented visits to the
institution within the last year with one day being
equivalent to either a single ED visit or an
admission to the hospital.
Statistical Analysis
Analyses were conducted using SigmaStat 3.5
Software® (Systat Software; San Jose, CA).
Antibiogram susceptibility rates and dichotomous
variables were assessed using chi-square and
multilogistic regression analysis was used to
compile risk factors for antimicrobial resistance and
risk factors for readmission. The level of
significance was set at a p-value of <0.05.
RESULTS
A total of 222 patients were identified as having
positive urine cultures and meeting all inclusion
criteria. According to the ED susceptibility profile,
levofloxacin- and SMX-TMP-susceptible E. coli
urinary tract infections were identified in 82.4% and
72.5% of cultures, respectively. According to the
institution’s hospital-wide antibiogram (January 1,
2010-December 31, 2010), levofloxacin- and SMXTMP-susceptible E. coli comprised 73% and 71% of
13
all isolates, respectively. There was noted to be a
significant difference in the rate of levofloxacin
susceptibility between these two groups (82.4%
versus 73%, p=0.003) but a non-significant
difference between the SMX-TMP groups (72.5%
versus 71%, p=0.690).
Significant risk factors for E. coli resistance to
levofloxacin included: male gender, age, presence
of hypertension, diabetes, chronic respiratory

P value
0.005
0.067
0.156
0.131
0.614
0.391
0.553
0.821
0.702
0.728
0.626
0.358

disease, nursing home resident, previous antibiotic
use, previous diagnosis of UTI, existence of renal or
genitourinary abnormalities, and prior surgical
procedures (Table 1). Logistic regression analysis
of risk factors for levofloxacin resistance found that
patient age was statistically significant (Table 2). No
significant difference was found in levofloxacin
resistance rates over 6- (p=0.145) or 12-month
(p=0.333) time periods (Table 3).
Risk factors for E. coli resistance to SMX-TMP are
outlined in Table 4. Prior antibiotic use (p=0.038)
and prior diagnosis of UTI (p= 0.012) were found to
be significantly different between groups. No
significant difference was found in SMX-TMP
resistance rates over 6- (p=0.655) or 12-month
(p=0.548) time periods (Table 5).
A total of 35 (15.8%) patients returned to the ED
with a diagnosis of a UTI. Of these 22 had an initial
prescription for levofloxacin and 11 had one for
TMP-SMX
(62.9%
vs.
31.4%,
p=0.169,
respectively). Characteristics that were found to be
significantly different between these two groups are
described in Table 6. Significantly higher
percentages of patients returned to the emergency
department if they had a previous diagnosis of a
urinary tract infection, renal or genitourinary
abnormalities, or prior antibiotic use. Logistic
regression analysis found that the number of
hospital days prior to the ED visit (p<0.001) was a
predictive factor in readmission (Table 7).
Of those patients prescribed a medication to which
their culture demonstrated susceptibility, 25 (13.7%)
returned to the ED with a diagnosis of a UTI and of
those prescribed inappropriate empiric therapy, 10
(25%) returned (p=0.126). Inappropriate empiric
therapy had a non-significant impact on hospital
length of stay if the patient had a return visit to the
ED or readmission to the hospital (OR: 1.222 [95%
CI 0.589-2.537]; p=0.590).
DISCUSSION
The findings of the present evaluation support
existing reports, which demonstrate changes in
resistance patterns of gram negative bacilli to
fluoroquinolones, particularly E. coli. The results of
the evaluation from Rattanaumpawan and

Table 3. Levofloxacin Resistance over Time
No. of total patients
No of patients with levofloxacin-resistant E. coli
Resistance rate (%)

1/09-6/09
31
0
0

7/09-12/09
30
7
23

1/10-6/10
31
6
19
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7/10-12/10
37
8
21.6

1/11-6/11
66
12
18.2

7/11-12/11
27
6
22.2
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Table 4. Risk Factors for E. coli Resistance to SMX-TMP
Category
SMX-TMP resistant
(n=61)
Sex, Male
11 (18.0%)
Race
White
49 (80.3%)
African-American
5 (8.2%)
Other
7 (11.5%)
Diabetes mellitus
13 (21.3%)
Hypertension
18 (29.5%)
Chronic respiratory disease
12 (19.7%)
Benign prostatic hypertrophy (BPH)
3 (4.9%)
Nursing home resident
5 (8.2%)
Antibiotic use within 90 days
32 (52.5%)
Previous UTI within 90 days
29 (47.5%)
Renal or genito-urinary abnormality
25 (41%)
Immunosuppression
8 (13.1%)
Home use of antibiotics
4 (6.6%)
Surgical procedures within 30 days
7 (11.5%)

colleagues confirmed fluoroquinolone resistance
10,11
This is contrary to information
approaching 20%.
captured from prior surveys in emergency
departments spanning the years from 2000-2004 in
which rates of E. coli susceptibility to
fluoroquinolones approached 93-95%.5,14 This
drastic change over a relatively short period of time
could be the result of increased fluoroquinolone use
in response to declining SMX-TMP susceptibilities.
Antimicrobial resistance is no longer an anomaly
seen only in the critically ill. It is important for
practitioners to be aware of its existence outside of
the hospital and for them to develop approaches to
identifying patients with patterns and risk factors for
resistance. Traditionally, guidance for identifying
patterns of resistance has been derived from
institutional antibiograms. An antibiogram provides
direction regarding institutional trends in bacterial
resistance and understanding these developments
helps avoid treatment failure or readmission to the
hospital.
Although this evaluation did not have the numbers
to detect a significant difference on rates of
readmission, understanding the association of
inappropriate therapies on rates of readmission
remains an important element in antimicrobial
stewardship. However, global application of an
institution-wide
antibiogram
to
all
patient
populations does not always translate into clinical
success. This is demonstrated by the ED
susceptibility profile derived from this evaluation, as
rates
of
fluoroquinolone
resistance
were
significantly different between the overall institution
and the ED. Per the hospital-wide antibiogram, E.
coli susceptibilities to levofloxacin and SMX-TMP
were 73 and 71%, respectively; whereas in the ED
susceptibility profile, 82.4% and 72.5% of isolates
were susceptible to levofloxacin and SMX-TMP,
13
respectively. Use of an inadequate antibiogram for
a unique patient population could result in
inappropriate empiric therapies, treatment failures,
and readmissions to the hospital, yielding potentially
significant healthcare and financial impacts.15

SMX-TMP susceptible
(n=161)
30 (18.6%)
121 (75.2%)
25 (15.5%)
15 (9.3%)
28 (17.4%)
52 (32.3%)
20 (12.4%)
6 (3.7%)
4 (2.5%)
58 (36.0%)
46 (28.6%)
67 (41.6%)
19 (11.8%)
9 (5.6%)
19 (11.8%)

p-value
0.928
0.526

0.633
0.812
0.247
0.984
0.122
0.038
0.012
0.946
0.970
0.963
0.868

The results of this investigation identified the
prevalence of resistance amongst E. coli isolates in
discharged patients, as SMX-TMP and levofloxacin
resistance rates exceeded guideline standards for
empiric therapy in the treatment of urinary tract
infection. In order to offer guidance on the selective
use of SMX-TMP and fluoroquinolones, previous
studies have attempted to identify risk factors for
resistance. Out of those evaluations, risk factors
identified for SMX-TMP resistance included: SMXTMP use within 30 days, diabetes mellitus, and
16-18
Age, fluoroquinolone use
recent hospitalization.
within the past year, prior hospitalization, diabetes
mellitus, hypertension, use of a foley catheter, and
urolithiasis were identified as risk factors for
16-19
However, these studies
levofloxacin resistance.
were either conducted outside of the United States
or before fluoroquinolone resistance was as
widespread as it is presently. This prevented
evaluators from determining the existence of
common risk factors for both SMX-TMP and
fluoroquinolones. In addition, neither inquiry
examined which risk factors were associated with
the most costly consequence of treatment failure,
hospital readmission rates. It was the intent of this
evaluation to assess whether any patient-specific
characteristics
could
be
associated
with
antimicrobial resistance. Those significant risk
factors that were identified included: age, co-morbid
conditions such as hypertension, diabetes, and
chronic respiratory disease, residing in a nursing
home, previous antibiotic use, previous diagnosis of
UTI, and existence of renal or genitourinary
abnormalities. Shared risk factors for SMX-TMP and
fluoroquinolone resistance included both previous
diagnosis of UTI and prior antibiotic use. This study
is limited by its retrospective nature and its
assessment of only the population treated by a
Level I Trauma Center. This evaluation was also
unable to characterize resistance rates for patients
admitted through the ED in addition to those
patients discharged from the ED. However, any
analysis of antimicrobial resistance rates must
always be institution specific and the identification of
risk factors for resistance has potential applicability
beyond single centers.

Table 5. SMP-TMP Resistance over Time
No. of total patients
No. of patients with levofloxacin-resistant E. coli
Resistance rate (%)

1/09-6/09
31
10
32.2

7/09-12/09
30
8
26.7

1/10-6/10
31
12
38.7
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7/10-12/10
37
9
24.3

1/11-6/11
66
15
22.7

7/11-12/11
27
7
25.9
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Table 6. Characteristics Associated with Return Visits to the Emergency Department (ED)
Characteristic, n (%)
Return ED Visit
No Return ED Visit
(n=35)
(n=187)
Levofloxacin Resistance
9 (25.7%)
30 (16.0%)
SMX-TMP Resistance
8 (22.9%)
53 (28.3%)
Previous Diagnosis of UTI
21 (60%)
54 (28.9%)
Renal/Genitourinary Abnormality
25 (71.4%)
67 (35.8%)
Antibiotic Use
26 (74.3%)
64 (34.2%)
Surgical Procedure
6 (17.1%)
20 (10.7%)
Immunosuppression
5 (14.3%)
22 (11.8%)
Prophylactic Use of Antibiotics
0 (0%)
3 (1.6%)

CONCLUSIONS
Identification of risk factors for resistance and
readmission should prompt providers to scrutinize
the use of these agents in the setting of patients
presenting with an uncomplicated UTI. This is
particularly imperative as the possibility of
resistance in patients with multiple risk factors (prior
UTI, antibiotic use within the previous 90 days, or
renal
or
genitourinary
abnormalities)
can
subsequently result in return visits to the ED or
increased rates of readmission. In addition, the
overall healthcare and financial impacts of choosing
the inappropriate empiric therapy could be

p-value
0.372
0.757
0.030
0.029
0.013
0.503
0.928
1.000

significant. Further study is needed to determine
whether optimal antimicrobial therapy can be
achieved through the risk stratification of patients
meeting these criteria subsequently leading to a
lower incidence of negative outcomes.
CONFLICT OF INTEREST
A.B.: No conflicts. K.W.: No conflicts. S.B: No
conflicts.
Financial support: There are no pertinent financial
relationships to disclose.

Table 7. Logistic Regression Analysis of Risk Factors for Readmission
Demographic
OR
95% CI
Age
1.000
0.980-1.022
Height
1.127
0.965-1.317
Weight
0.898
0.772-1.044
Body Mass Index (BMI)
1.355
0.906-2.028
Hospital days prior
1.100
1.053-1.149

P value
0.974
0.131
0.162
0.139
<0.001
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